摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Butyl-2-chlor-N-methylacetamid | 39096-59-8

中文名称
——
中文别名
——
英文名称
N-Butyl-2-chlor-N-methylacetamid
英文别名
N-butyl-2-chloro-N-methylacetamide
N-Butyl-2-chlor-N-methylacetamid化学式
CAS
39096-59-8
化学式
C7H14ClNO
mdl
MFCD03030385
分子量
163.647
InChiKey
FMDCVGFKCSILHT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    10
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 危险等级:
    IRRITANT

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and antihypertensive activity evaluation in spontaneously hypertensive rats of lacidipine analogues
    摘要:
    Six analogues of lacidipine, (E)-diethyl 4-(2-(3-amino)-3-oxoprop-1-enyl)phenyl-2, 6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylates (compounds 1-6), were synthesized and their antihypertensive effects in spontaneously hypertensive rats were evaluated by ig administration. Amongst the tested compounds, compound 5 exhibited the highest antihypertensive effect. The lasting time and potency of compound 5 showed a dose-dependent manner. The results suggested that N-tert-butyl acrylamide moiety at 2'-position of 4-phenyl in the structure of analogues of lacidipine is necessary to keep antihypertensive effects.
    DOI:
    10.1007/s00044-011-9680-7
点击查看最新优质反应信息

文献信息

  • HCV PROTEASE INHIBITORS AND USES THEREOF
    申请人:Niu Deqiang
    公开号:US20090176858A1
    公开(公告)日:2009-07-09
    The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    本发明提供了化合物、药学上可接受的组合物以及使用它们的方法。
  • ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
    申请人:Singh Juswinder
    公开号:US20100185419A1
    公开(公告)日:2010-07-22
    The invention is an algorithm and method for designing an inhibitor that covalently binds a target polypeptide. The algorithm and method can be used to rapidly and efficiently convert reversible inhibitors into irreversible inhibitors.
    这项发明是一种用于设计与靶多肽共价结合的抑制剂的算法和方法。该算法和方法可用于快速高效地将可逆抑制剂转化为不可逆抑制剂。
  • PI3 KINASE INHIBITORS AND USES THEREOF
    申请人:NIU DEQIANG
    公开号:US20110230476A1
    公开(公告)日:2011-09-22
    The present invention provides compounds, compositions thereof, and methods of using the same.
    本发明提供了化合物、其组合物以及使用相同的方法。
  • Selective Estrogen Receptor Modulator
    申请人:Hamaoka Shinichi
    公开号:US20120004315A1
    公开(公告)日:2012-01-05
    The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.
    本发明提供一种由以下式(I)表示的化合物; [其中T表示单键,可能具有取代基的C1-C4烷基和类似物;式(I-1)表示单键或双键;A表示单键,可能具有取代基的双价5-至14-成员杂环基和类似物;Y表示单键和类似物;Z表示亚甲基基团和类似物;环G表示苯基团和类似物,可能与5-至6-成员环缩合并可能具有杂原子;Ra和Rb相同或不同,表示氢原子和类似物;W表示单键和类似物;R'表示1到4个独立的氢原子和类似物;R''表示1到4个独立的氢原子和类似物]或其盐或水合物。
  • Selective estrogen receptor modulator
    申请人:Hamaoka Shinichi
    公开号:US20060116364A1
    公开(公告)日:2006-06-01
    The present invention provides a compound represented by the following formula [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof
    本发明提供了一种化合物,其表示为以下式子[其中T表示单键,C1-C4的烷基,可能带有取代基等;式(I-1)表示单键或双键;A表示单键,二价的5-至14-成员杂环基团,可能带有取代基等;Y表示单键等;Z表示亚甲基等;环G表示苯基团等,可与5-至6-成员环缩合并且可能具有杂原子;Ra和Rb相同或不同,表示氢原子等;W表示单键等;R'表示1至4个独立的氢原子等;R"表示1至4个独立的氢原子等]或其盐,或其水合物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物